Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: 'Long COVID: Research, Policy, and Economic Impact' on May 19, 2022
5
6
7
8
9
10
11
12
13
14
15
<<
<
>
>>
Privacy